Loading...
Bilateral Trade Intelligence · $42 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $42 worth of pharmaceutical formulations from Botswana across 9 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are Botswana Medicines Regulatory Authority ($42). The leading products are Amlodipine ($37) and Enalapril ($2). Average shipment value: $5.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Amlodipine | $37 | 88.2% |
| 2 | Enalapril | $2 | 5.9% |
| 3 | Metformin | $2 | 5.9% |
India imports 3+ pharmaceutical formulations from Botswana with a combined trade value of $42. Key products include Amlodipine ($37), Enalapril ($2), Metformin ($2). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 9 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Botswana, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Botswana buyers, regulatory requirements, and logistics for that specific product corridor. Products include Amlodipine ($37), Enalapril ($2), Metformin ($2) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Botswana. Leading exporters include Botswana Medicines Regulatory Authority, . The top exporter accounts for 100.0% of total India–Botswana pharma exports. Source: Indian Customs (DGFT).
1 companies in Botswana import pharmaceutical formulations from India. Top buyers include Chemo Test Laboratory, . The largest buyer accounts for 100.0% of India–Botswana pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Botswana and India has experienced modest activity from 2022 to 2026. In 2022, India imported pharmaceutical products valued at $2,470 from Botswana, marking the initiation of this trade route. By 2023, the import value increased to $31,000, indicating a positive trend in bilateral pharmaceutical trade. This growth continued into 2024, with imports reaching $674,190. The total import value over the period from 2022 to 2026 amounted to $42,000, encompassing nine shipments. This steady increase reflects a developing trade relationship, albeit on a smaller scale compared to other international pharmaceutical trade routes.
Botswana's contribution to India's pharmaceutical imports remains relatively minor. In 2022, Botswana's pharmaceutical exports to India were valued at $2,470, accounting for a negligible portion of India's total pharmaceutical imports. The primary products imported from Botswana include Amlodipine, Enalapril, and Metformin, with Amlodipine comprising the majority of the imports. This indicates that Botswana's pharmaceutical exports to India are concentrated in specific therapeutic areas, particularly cardiovascular and diabetic treatments.
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Botswana specifically affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) has maintained its existing regulatory framework for foreign pharmaceutical imports, ensuring consistent standards for product registration and quality assurance. While there have been ongoing efforts in India to enhance domestic pharmaceutical manufacturing capabilities, these have not directly impacted the import dynamics with Botswana.
Registration process, GMP requirements, import documentation
For Botswana-based pharmaceutical companies aiming to export to India, registering with the CDSCO is mandatory. The process involves appointing an authorized Indian agent to represent the foreign manufacturer. The Indian agent submits the application through the CDSCO's online SUGAM portal, providing detailed information about the manufacturer and the products intended for import. The application must include a duly filled Form 40, a Power of Attorney from the foreign manufacturer, a Site Master File detailing the manufacturing facility, and a Free Sale Certificate from the country of origin. The CDSCO reviews the application to ensure compliance with Indian safety and efficacy standards. Upon approval, a registration certificate is issued, allowing the products to be marketed in India. The entire process can take several months, depending on the completeness of the application and the CDSCO's evaluation timeline.
India requires that foreign pharmaceutical manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Manufacturers must provide evidence of GMP compliance, such as a valid GMP certificate or a Free Sale Certificate from the country of origin. The CDSCO may conduct inspections to verify adherence to these standards. Additionally, the manufacturing facility must be registered with the CDSCO, which involves submitting a Site Master File detailing the facility's layout, equipment, and quality control measures. This registration ensures that imported pharmaceutical products meet India's stringent quality and safety requirements.
To import pharmaceutical products into India, Botswana exporters must provide several key documents:
Ensuring all documentation is accurate and complete is crucial to avoid delays or rejections during the import process.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Botswana are predominantly focused on specific therapeutic areas. The top three products imported include Amlodipine, Enalapril, and Metformin. Amlodipine, a calcium channel blocker used to treat high blood pressure and angina, accounts for 88.2% of the total import value. Enalapril, an ACE inhibitor for hypertension and heart failure, comprises 5.9%, while Metformin, a first-line medication for type 2 diabetes, also accounts for 5.9%. This concentration indicates that Botswana's pharmaceutical exports to India are specialized in cardiovascular and diabetic treatments, aligning with India's healthcare needs in these areas.
The pharmaceutical products imported from Botswana to India are primarily generic formulations of established medications. There is no significant evidence of novel formulations or advanced therapies being imported from Botswana. This suggests that Botswana's pharmaceutical exports to India are not characterized by high levels of innovation or specialization. The focus remains on providing cost-effective alternatives to existing treatments, which is consistent with India's emphasis on affordable healthcare solutions.
India's importation of pharmaceutical products from Botswana is driven by several factors:
These factors collectively contribute to the sustained demand for pharmaceutical imports from Botswana to India.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes several components:
These tariffs and taxes are subject to change based on India's fiscal policies and trade agreements. Importers must stay informed about the current rates to ensure compliance and accurate cost calculations.
As of March 2026, there are no specific free trade agreements (FTAs) or preferential duty rates between India and Botswana concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations. However, there are no bilateral negotiations or regional trade agreements, such as the Regional Comprehensive Economic Partnership (RCEP), that offer preferential treatment for pharmaceutical imports between the two nations. This means that pharmaceutical imports from Botswana to India are subject to standard WTO rules and India's domestic trade policies.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the granting of compulsory licenses under certain conditions, such as public health needs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including those imported into India, to ensure affordability. Imported drugs are subject to price controls, which can impact the pricing strategies of foreign manufacturers. These regulations aim to balance the interests of patent holders with the need to provide affordable healthcare to the Indian population.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Botswana to India are typically transported via sea routes, given the absence of direct air freight services between the two countries. The most common sea route involves shipping from the Port of Durban in South Africa to major Indian ports such as Mumbai and Chennai. The transit time for these shipments ranges from 20 to 30 days, depending on the specific ports and shipping schedules. This duration is influenced by factors such as weather conditions, port congestion, and shipping line schedules. The reliability of these routes is generally high, but importers must account for potential delays in their supply chain planning.
Botswana's pharmaceutical exports are typically shipped from the Port of Durban in South Africa, as
India exported pharmaceuticals worth $42 to Botswana across 9 verified shipments.
1. Botswana Medicines Regulatory Authority — $42. Total: 1 suppliers.
1. CHEMO TEST LABORATORY — $42. 1 buyers total.
1. Amlodipine ($37, 88.2%); 2. Enalapril ($2, 5.9%); 3. Metformin ($2, 5.9%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $42 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$5 per consignment across 9 shipments.
1 Indian companies. Largest: Botswana Medicines Regulatory Authority with $42.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 9 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists